Synonyms that are in the dictionary are marked in green. Synonyms that are not in the dictionary are marked in red.
Antonyms that are in the dictionary are marked in green. Antonyms that are not in the dictionary are marked in red.
Finally, Lifesci Capital reiterated an “outperform” rating on shares of Akero Therapeutics in a research report on Tuesday, April 11th.
In other Akero Therapeutics news, CEO sold 25,000 shares of the firm’s stock in a transaction on Monday, May 1st.
In other news, COO sold 8,777 shares of Akero Therapeutics stock in a transaction dated Tuesday, January 3rd.
JPMorgan Chase & Co. Increases Akero Therapeutics (NASDAQ:AKRO) Price Target to $62.
Source: https://www.etfdailynews.com/2023/09/09/american-airlines-group-nasdaqaal-upgraded-at-bnp-paribas/
MetLife Investment Management LLC lifted its holdings in shares of Akero Therapeutics by 58.5% during the 1st quarter.
Point72 Asset Management L.P. raised its holdings in Akero Therapeutics by 24.5% in the second quarter.
Swiss National Bank raised its stake in Akero Therapeutics by 7.8% during the first quarter.